Adam Kichler, DO, is a gastroenterologist and advanced endoscopist at Allegheny Health Network.

Bridging the Gap in EPI Diagnosis and Management

Greasy, foul-smelling stools and persistent bloating are often dismissed as routine gastrointestinal complaints, but they can signal a more overlooked issue. Exocrine pancreatic insufficiency (EPI) remains a frequently missed contributor to gastrointestinal symptom burden, in part because its clinical presentation so often overlaps with more commonly diagnosed conditions.

As Adam Kichler, DO, a gastroenterologist and advanced endoscopist at Allegheny Health Network, emphasized in an interview with 

, hallmark features like bloating, loose stools, and particularly greasy, foul-smelling stools should prompt consideration of EPI, especially in patients with known pancreatic disease such as chronic pancreatitis. He also calls attention to the more clinically challenging and arguably more underrecognized population of those with so-called “secondary EPI,” particularly individuals with inflammatory or malabsorptive disorders.

The overlap with conditions like Crohn's disease and celiac disease is especially important. Both are independently associated with diarrhea and malabsorption, which can obscure a concurrent diagnosis of EPI. Kichler highlights that up to 20% of patients with these conditions may also have EPI, not due to intrinsic pancreatic failure, but rather impaired signaling from the inflamed small intestine.

“In addition to providing pancreatic enzymes as a kind of bridge to get people feeling better, the mainstay of treatment is to address the underlying small bowel disease, and then the EPI should rectify itself afterwards,” he explained.

From a diagnostic standpoint, the field has largely coalesced around indirect testing strategies. Stool-based assessments, particularly fecal elastase and spot fecal fat, offer a practical and noninvasive approach that aligns with real-world clinical workflows. Although direct pancreatic function testing remains the gold standard, its invasiveness and logistical complexity limit widespread use. In practice, Kichler says the emphasis is on balancing diagnostic accuracy with feasibility, an area where indirect testing has proven sufficient for most patients.

Treatment, however, introduces its own set of challenges. Pancreatic enzyme replacement therapy remains the cornerstone of management, most commonly with pancrelipase capsules like Creon, Zenpep, Pancreaze, Pertzye, and Viokace.

However, underdosing is a pervasive issue. As Kichler notes, appropriate initiation—typically around 40,000 to 50,000 units of lipase per meal, with titration based on response—is critical to achieving symptom control.

Equally important is proper administration timing and ensuring coverage for snacks, both of which can significantly impact therapeutic efficacy. Beyond enzyme replacement, comprehensive care requires attention to nutritional deficiencies, particularly fat-soluble vitamins, and longitudinal monitoring to ensure adequacy of repletion.

Kichler additionally underscores premature initiation of PERT without adequate evaluation as a key clinical pitfall. In patients without clear pancreatic pathology, he says alternative causes of malabsorption must be excluded before committing to lifelong enzyme therapy.

Ultimately, Kichler notes improving outcomes in EPI requires a more deliberate approach prioritizing accurate diagnosis, avoiding premature treatment, and recognizing its overlap with other GI disorders. While pancreatic enzyme replacement therapy is effective, he emphasizes that its success hinges on proper dosing, monitoring, and addressing underlying causes, particularly in secondary EPI.

Editors’ Note: Kichler reports no relevant disclosures.

Cleveland Clinic. Exocrine Pancreatic Insufficiency (EPI). June 10, 2021. Accessed March 19, 2026. 

https://my.clevelandclinic.org/health/diseases/21577-exocrine-pancreatic-insufficiency-epi

NIDDK. Definition & Facts for Exocrine Pancreatic Insufficiency. January 2023. Accessed March 19, 2026. 

https://www.niddk.nih.gov/health-information/digestive-diseases/exocrine-pancreatic-insufficiency/definition-facts

Drugs.com. Medications for Pancreatic Exocrine Dysfunction. March 19, 2026. 

https://www.drugs.com/condition/pancreatic-exocrine-dysfunction.html

Videos

Kichler notes that EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offers key insights on diagnosis and management.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Diagnostic Challenges and Clinical Nuance of EPI, With Adam Kichler, DO

Christine Limonte is an assistant professor at UW Medicine and a study investigator for the Kidney Precision Medicine Project.

Rethinking Diabetic and Hypertensive CKD Through the Lens of Precision Medicine

Kidney biopsies in patients with common forms of chronic kidney disease (CKD) reveal unexpected diagnoses, unsuspected disease processes, and findings that standard frameworks often miss, challenging long-held assumptions about what diabetic and hypertensive kidney disease actually looks like.

Investigators from the Kidney Precision Medicine Project (KPMP), a multi-center consortium pursuing comprehensive clinical, histopathological, and molecular characterization of kidney disease, highlighted the clinical utility of research biopsies in a broader CKD population, beyond the high-risk or severe presentations where biopsies have traditionally been performed.

In a pilot cohort of 39 adults with CKD due to diabetes or hypertension, over a quarter of treating clinicians were surprised by biopsy results, and in 77% of cases, findings directly shaped prognostic discussions. Unsuspected diagnoses, acute processes, and nonspecific findings were common, suggesting that the true histopathologic landscape of diabetic and hypertensive kidney disease is far broader than clinical labels imply. For a field that has long relied on those labels to guide care, these findings raise an important question: how much are we missing?

"In addition to these completely unexpected diagnoses such as IGA nephropathy and fibrillary glomerulonephritis, which would prompt a change in management, we frequently observed acute tubular injury and inflammatory infiltrates, which are not traditionally incorporated into our classic frameworks for diabetic nephropathy and hypertension associated kidney disease," said study investigator Christine Limonte, MD, assistant professor of medicine at UW Medicine.

These findings point to a fundamental gap in how diabetic and hypertensive kidney disease has traditionally been understood, one built largely around glomerular pathology and severe clinical presentations, leaving tubular, interstitial, and vascular injury undercharacterized. KPMP's ability to pair detailed biopsy review with molecular data offers a path toward filling that gap, and potentially toward classifying patients by the specific biology driving their disease rather than by diagnosis alone.

"I think there's a lot of potential here, especially within the Kidney Precision Medicine Project, to dive further into those specific lesions and use the molecular data that's being obtained to better understand the underlying biology of those lesions and potentially get to a point where we can subtype someone's diabetic nephropathy or diabetes related chronic kidney disease based on their specific patterns of biopsy findings," Limonte added.

Editor’s Note: Limonte reports no relevant disclosures.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Professor of Immunology and Allergy at Imperial College London and 
European Academy of Allergy and Clinical Immunology (EAACI) Secretary General

PQ Grass Allergy Immunotherapy: Shared Decision-Making and What's Next, With Mohamed Shamji, PhD

View part 1 of our conversation with Shamji here.

With 6-injection PQ Grass 27,600 SU now backed by mechanistic and clinical data — including a 22.5% improvement in Combined Symptom Medication Score over placebo (

 <.00004) across pooled analyses of PQG309 and PQG306 (n = 75; PQ Grass, n = 40; placebo, n = 35), atop a placebo response commonly reaching 50% — the conversation around allergen immunotherapy is shifting from whether these treatments work to how clinicians and patients choose among an expanding set of options.

In the second part of our conversation with Mohamed Shamji, PhD, Professor of Immunology and Allergy at Imperial College London and Secretary General of the European Academy of Allergy and Clinical Immunology, at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, the focus turned to shared decision-making, the evidence gaps he most wants to see addressed, and the broader preventive potential of immunotherapy. 

Shamji was emphatic that treatment selection — among subcutaneous, sublingual, and accelerated pre-seasonal regimens like PQ Grass — must be driven by patient preference and lifestyle rather than physician default. Some patients find the structured clinic visit commitment of subcutaneous immunotherapy reassuring; others, particularly frequent travelers or those unable to keep regular appointments, are better served by home-based sublingual tablets. Adherence, he noted, is a persistent challenge across all AIT modalities — paradoxically, in part because immunotherapy works: patients who become symptom-free during treatment may stop taking it, just as they might stop a short course of antihistamines once symptoms resolve. The 6-injection model addresses this directly by compressing the entire pre-seasonal course into a small number of clinic visits, removing the daily compliance burden entirely. For pediatric patients, he added, needle aversion introduces an additional layer of complexity that makes route of administration a particularly important part of the shared decision.

On evidence gaps, Shamji identified objective predictive biomarkers as the priority he most wants to see developed alongside PQ Grass. The mechanistic data from PQG309 and PQG306 already demonstrate a clear tolerogenic immune signature — with statistically significant induction of sIgG, sIgG4, sIgA1, and sIgA2 (

 <.01), functional inhibition of allergen-IgE complex binding to B cells pre- and post-season (

 <.01 respectively), and suppression of Th2 and Th2A proliferation (

 <.05) — but translating those signals into validated, patient-facing biomarkers that can demonstrate treatment trajectory in real time remains an unmet need his group at Imperial is actively working toward. 

Finally, Shamji broadened the frame to immunotherapy's preventive dimension — its established ability to prevent new sensitizations and reduce progression to asthma — and previewed early data from his group on virus-like particles expressing the Fel d 1 molecule for cat allergy, which showed promising safety and efficacy in a first-in-human study, pointing toward a new generation of precision immunotherapy platforms he described as the genuinely exciting frontier of the field.

Shamji’s disclosure information was not available.

Layhadi J, Starchenka S, de Kam PJ, et al. PQ Grass 27600 SU effectively induces tolerogenic properties through modulation of humoral and cellular immune responses for the treatment of seasonal allergic rhinitis. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L77

Shamji shared the factors influencing which treatments are best for each patient and further research he'd like to see.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Seasonal Allergy

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Balázs Szigeti, PhD, from the Translational Psychedelic Research Program at University of California San Francisco (UCSF)

Psychedelics vs Antidepressants: New Study Challenges the Hype

New findings suggest the perceived advantage of psychedelic-assisted therapy (PAT) for 

 may reflect trial design rather than superior efficacy.

“Psychedelics have generated a lot of hype… When are trying to incorporate how to analyze this issue of functional unblinding into the trials, I would say there is enough good stuff left about psychedelics that is worth looking into, but maybe the efficacy and the promise have been oversold by those early research that did not pay attention to these methodological issues,” said investigator Balázs Szigeti, PhD, from the Translational Psychedelic Research Program at University of California San Francisco (UCSF), in an interview with 

In a recent meta-analysis, Szigeti and colleagues found no statistically significant difference in symptom improvement between PAT and open-label traditional antidepressants (TADs) when accounting for functional unblinding, a known challenge in psychedelic trials. The analysis included 24 studies and compared within-arm changes in depression severity.

, lead investigator Balázs Szigeti, PhD, emphasized that clinicians often focus on between-group differences, assessing how much better a treatment performs than placebo, rather than the total magnitude of symptom improvement experienced by patients.

“That is only half of the story. That just tells you how much better [the treatment] is than the placebo,” Szigeti said. “You really need to know where that baseline [is]... to really interpret this study.”

The analysis found that PAT and open-label antidepressants produced nearly identical reductions in depression scores, with an estimated difference of just 0.3 points on the Hamilton Depression Rating Scale (HAM-D) (95% confidence interval [CI], −1.39 to 1.98; 

 =.73). These results challenge earlier narratives suggesting psychedelics may offer substantially greater efficacy than standard pharmacotherapy.

A key factor underlying this discrepancy is functional unblinding. Due to the pronounced subjective effects of psychedelics, patients in these trials can often correctly guess their treatment assignment. Szigeti noted that correct guess rates reach approximately 90–95% in psychedelic studies, compared with about 60% in antidepressant trials.

This phenomenon, referred to as the “know-cebo” effect, may be particularly pronounced in psychedelic trials, where participants often enter with high expectations of a transformative experience. When those expectations are not met, outcomes in the control arm may fall well below typical placebo responses seen in antidepressant studies.

“Psychedelics are a very exciting new treatment option,” he said. “A lot of people would like to get it, and they sign up for these trials…it's a lot of paperwork and a lot of effort to participate in these trials. You have to fill out all of the questionnaires, go to the hospital several times, and you also have preparatory psychotherapy. In this psychotherapy, we are typically telling the patients that you know you're going to have this likely life, transformative, mind-expanding experience, a spiritual transformation…we're really building it up in these preparatory therapy sessions. And then, for the unlucky patients, they show up for dosing, they take the capsule, and then nothing happens. Of course, they are disappointed. I know I would be disappointed.”

Szigeti cautioned against interpreting these findings as evidence that psychedelics are ineffective.

“What we show is not that psychedelics are not effective. We are just showing that they are not more effective than open-label antidepressants,” he said. “What this means in practice is that it just seems that the magnitude of the improvement that can be achieved with these 2 treatment modalities [is] the same.”

Williams ZJ, Barnett H, Szigeti B. Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions: A Systematic Review and Meta-Analysis. 

Meta-analysis shows psychedelic-assisted therapy offers similar symptom improvement to open-label antidepressants under equal unblinding conditions.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Psychedelic Therapy Matches Efficacy of Antidepressants in MDD, With Balázs Szigeti, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved a new higher dose of Novo Nordisk’s semaglutide (Wegovy; Wegovy HD) injection 7.2 mg to be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for ≥ 4 weeks and additional weight reduction is clinically indicated.

As described in a March 19, 2026, press release from the Company, the approval is based on the results from the STEP UP trial program. Of note, the new update supplements the existing semaglutide label, which also has distinct indications for semaglutide not offered by any other GLP-1 medication for weight loss.

"Wegovy® HD represents an important new tool in obesity management, allowing clinicians to better tailor treatment strategies and help improve outcomes," W Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, said in a statement. "The weight loss demonstrated with Wegovy® HD could reshape healthcare professionals' expectations about what outcomes are possible for their patients with Wegovy®."

The FDA initially approved semaglutide 2.4 mg in June 2021 for chronic weight management in adults with obesity or overweight, marking a landmark approval for the GLP-1 RA class. A label expansion in March 2024 added an indication for reduction of cardiovascular risk among adults with obesity or overweight, based on results from the SELECT trial.

Prior to the approval of Wegovy HD, the highest approved dose of semaglutide injectable for weight loss was 2.4 mg, which is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.

The newest approval is based on the results of the STEP UP trial program. STEP UP was a phase 3b 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention. A total of 1407 adults with BMI ≥30 kg/m2 without diabetes were included in the trial.

The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss after 72 weeks with respect to the percentage change in body weight and the proportion of participants achieving weight loss of ≥ 5%. Select confirmatory secondary endpoints included number of participants achieving ≥10%, 15%, 20% and 25% weight loss, with semaglutide 7.2 mg vs placebo (and for ≥ 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg).

In total, 1407 participants were randomly assigned in a 5:1:1 ratio to receive once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo, alongside lifestyle intervention, for 72 weeks.

Topline results from the trial were announced in January 2025 and showed statistically significant and superior weight loss at 72 weeks with semaglutide 7.2 mg, compared with placebo, irrespective of treatment adherence.

As described in the release from Novo Nordisk, for those taking Wegovy HD, 89% achieved ≥ 5% body weight loss versus 38% taking placebo (from a baseline body weight of 248 lbs).

The most common adverse reactions reported with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence. In clinical trials, dysesthesia was reported at a higher rate with Wegovy HD compared to semaglutide 2.4 mg and placebo.

Events related to a clinical picture of altered skin sensation such as sensitive skin, hyperesthesia, dysesthesia and paresthesia were reported by a greater proportion of participants, and at a higher rate, in the Wegovy HD arm (22%), compared to treatment with semaglutide 2.4 mg (6%) and placebo (0.3%).

As described in the press release from Novo Nordisk, Wegovy HD will be available in April through all channels where patients can access semaglutide, including 70,000 plus pharmacies in the US like CVS and Costco, select telehealth providers, NovoCare Pharmacy, GoodRx, and others.

"We are excited to bring Wegovy® HD injection to adults with obesity who are looking for powerful weight loss, as no other weight loss medicine has been studied to show superiority to Wegovy® HD," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "In addition to significant weight loss, Wegovy® is the only GLP-1 for adults with obesity that is proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Today's milestone expands the strong clinical profile of Wegovy® that includes multiple indications that no other GLP-1 for weight loss can claim."

Novo Nordisk. FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile. March 19, 2026. Accessed March 19, 2026. 

https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html

Iapoce C. Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial. HCPLive. January 17, 2025. Accessed March 19, 2026. 

https://www.hcplive.com/view/semaglutide-7-2-mg-displays-20-7-weight-loss-in-phase-3b-step-up-trial

Articles

FDA approval of semaglutide 7.2 mg (Wegovy HD) expands dosing options for chronic weight management in adults with obesity without diabetes who have tolerated 2.4 mg for at least four weeks and need further weight reduction. The decision is supported by STEP UP, a 72-week phase 3b randomized, double-blind, placebo- and active-controlled superiority trial comparing 7.2 mg with 2.4 mg and placebo alongside lifestyle intervention. High-dose semaglutide increased clinically meaningful weight loss but showed higher rates of altered skin-sensation events.

The approval is based on results from the STEP UP trial program showing substantial weight loss in adults with obesity. 

FDA News

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity

Doug Simonetto, MD, is a Mayo Clinic transplant hepatologist.

AI-enabled ECG may help detect liver disease earlier, offering a new path to close diagnostic gaps and shift toward preventive hepatology in clinical practice.

Hepatology

Improving Early Liver Disease Diagnosis With AI ECG, With Doug Simonetto, MD

Allergist-immunologist at Yale New Haven Hospital

Su described how NNAALs drive management decisions in pregnancy and post partum care.

Non-Narcotic Analgesic Allergy Labels in Pregnancy Drive Suboptimal Care and Adverse Outcomes, With Chang Su, MD

The first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist delivered superior A1C reduction and weight loss at 40 weeks in people with type 2 diabetes.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Retatrutide Delivers A1C Reduction, Weight Loss in Phase 3 TRANSCEND-T2D-1 Trial

Maya Clark Cutaia, PhD, RN, is the inaugural Evelyn Lauder Associate Dean for Nurse Practitioner Programs and Professor at the Hunter-Bellevue School of Nursing at Hunter College.

An expert breaks down how poverty, limited healthcare access, and geographic barriers delay CKD diagnosis, reduce transplant access, and widen health disparities, and what clinicians can do about it.


Neighborhood Disadvantage and Its Downstream Effects on Equitable Kidney Care, With Maya Clark Cutaia, PhD, RN

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

AAD 2026 Preview: Late Breaking Data to Watch

Experts examine how the guidelines represent the evidence base for each step-up agent and address the limited role of laboratory testing in driving treatment decisions.

Interpreting the Treatment Algorithm: Evidence Levels, Diagnostic Workup, and the Stepwise Framework 

Accelerated 5×5 rTMS delivers comparable outcomes to standard protocols, offering faster treatment with key tradeoffs in cost, access, and response timing.

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

Experts discuss how clinicians can use patient preferences, comorbidities, route of administration, and access considerations to guide decisions.

Individualized Therapy Selection: Shared Decision-Making Among Omalizumab, Dupilumab, and Remibrutinib

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Expanding the Role of Finerenone in CKD Care, With Brendon Neuen, MBBS, PhD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Latest News

Diagnostic Challenges and Clinical Nuance of EPI, With Adam Kichler, DO

Rethinking Diabetic and Hypertensive CKD Through the Lens of Precision Medicine

PQ Grass Allergy Immunotherapy: Shared Decision-Making and What's Next, With Mohamed Shamji, PhD

Psychedelic Therapy Matches Efficacy of Antidepressants in MDD, With Balázs Szigeti, PhD

FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity